Loading data for PALI — first visit, this takes a few seconds.
Palisade Bio Inc. (PALI)
NasdaqCM: PALI
· Precio en tiempo real · USD
2.04
-0.11 (-5.12%)
Al cierre: Aug 18, 2026, 3:59 PM
Palisade Bio Inc. (PALI) Stock Price, Analysis & Data
-5.12% (1D)
| Precio de compra | n/a |
| Capitalización de mercado | 355.51M |
| Ingresos (TTM) | 500K |
| Beneficio neto (TTM) | -31.94M |
| Beta | 1.54 |
| EPS (TTM) | 0.61 |
| Ratio PER (TTM) | 3.34 |
| Adelante PE | -7.29 |
| P/B (TTM) | 2.91 |
| P/S (TTM) | 711.02 |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | 2,285,257 |
| Volumen medio (20D) | 3,141,403 |
| Abierto | 2.15 |
| Anterior Cerrar | 2.15 |
| Rango del día | 2.01 - 2.15 |
| Rango de 52 semanas | 0.53 - 2.86 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...
Industria Biotechnology
Sector Healthcare
IPO Fecha Mar 30, 2007
Empleados 14
Bolsa de Valores NasdaqCM
Símbolo bursátil PALI
Sitio web https://www.palisadebio.com
Desempeño financiero
En 2025, los ingresos de Palisade Bio fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -16.78M, un aumento de 16.23%.
Estados financierosSorpresa de resultados
Palisade Bio ha publicado sus resultados trimestrales en Aug 10, 2026:
Página 1 de 2